BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21911055)

  • 1. The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR.
    Zhou X; Agazie YM
    Cell Signal; 2012 Jan; 24(1):140-50. PubMed ID: 21911055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
    Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
    J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling.
    Hartman Z; Zhao H; Agazie YM
    Oncogene; 2013 Aug; 32(35):4169-80. PubMed ID: 23027125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
    Huang Y; Kim SO; Jiang J; Frank SJ
    J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes.
    Munk M; Memon AA; Goetze JP; Nielsen LB; Nexo E; Sorensen BS
    PLoS One; 2012; 7(7):e40243. PubMed ID: 22792252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.
    Nava M; Dutta P; Zemke NR; Farias-Eisner R; Vadgama JV; Wu Y
    BMC Med Genomics; 2019 Feb; 12(1):32. PubMed ID: 30736768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research.
    Earp HS; Dawson TL; Li X; Yu H
    Breast Cancer Res Treat; 1995 Jul; 35(1):115-32. PubMed ID: 7612898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling.
    Wong L; Deb TB; Thompson SA; Wells A; Johnson GR
    J Biol Chem; 1999 Mar; 274(13):8900-9. PubMed ID: 10085134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes.
    Wu CJ; Qian X; O'Rourke DM
    DNA Cell Biol; 1999 Oct; 18(10):731-41. PubMed ID: 10541432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms.
    Hendriks BS; Wiley HS; Lauffenburger D
    Biophys J; 2003 Oct; 85(4):2732-45. PubMed ID: 14507736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
    Monsey J; Shen W; Schlesinger P; Bose R
    J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling.
    Graus-Porta D; Beerli RR; Hynes NE
    Mol Cell Biol; 1995 Mar; 15(3):1182-91. PubMed ID: 7532277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
    Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.
    Yao W; Feng D; Bian W; Yang L; Li Y; Yang Z; Xiong Y; Zheng J; Zhai R; He J
    Amino Acids; 2012 Nov; 43(5):2027-35. PubMed ID: 22476347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.